Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 6/20 | 0.56 |
| ▸ | MAOB | P27338 | 3/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.55 |
| ▸ | SDHA | P31040 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CALML3 | P27482 | 1/20 | 0.55 |
| ▸ | F10 | P00742 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7107786 | 1.00 | MAOA (0.56) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6040350 | 0.95 | MAOA (0.57) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6040357 | 0.88 | MAOA (0.56) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6040425 | 0.87 | MAOA (0.49) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL5209849 | 0.85 | MAOA (0.64) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6396680 | 0.85 | MAOA (0.65) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6396676 | 0.85 | MAOA (0.65) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL8307010 | 0.85 | MAOA (0.59) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL8307008 | 0.85 | MAOA (0.59) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6398570 | 0.84 | MAOA (0.60) | MAOAMAOBPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0717738-B1 | SUBSTITUTED OXAZINE AND THIAZINE OXAZOLIDINONE ANTIMICROBIALS | UPJOHN CO (US) | 1999-10-20 | — | — | EP | claimed |
| US-20030171331-A1 | The present invention describes a novel cotherapy of oxazolidinones and at least one vitamin selected from vitamin B2, vitamin B6, vitamin B12 and folic acid. | PHARMACIA & UPJOHN COMPANY | 2003-09-11 | — | — | US | disclosed |
| EP-0717738-B1 | SUBSTITUTED OXAZINE AND THIAZINE OXAZOLIDINONE ANTIMICROBIALS | UPJOHN CO (US) | 1999-10-20 | — | — | EP | disclosed |
| EP-0717738-A1 | SUBSTITUTED OXAZINE AND THIAZINE OXAZOLIDINONE ANTIMICROBIALS | PHARMACIA & UPJOHN COMPANY (US) | 1996-06-26 | — | — | EP | disclosed |
| WO-1995007271-A1 | SUBSTITUTED OXAZINE AND THIAZINE OXAZOLIDINONE ANTIMICROBIALS | THE UPJOHN COMPANY (US) | 1995-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171331-A1 | The present invention describes a novel cotherapy of oxazolidinones and at least one vitamin selected from vitamin B2, vitamin B6, vitamin B12 and folic acid. | DHFR, MMAB, FOLR2 | MAOA 252/4885MAOB 13/4885PTGS1 2165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.